Cognitive effects of cell-derived and synthetically derived Aβ oligomers

Neurobiology of Aging

Volumn 32, Issue 10, 2011, Pages 1784-1794

  Reed, Miranda N ^a   Hofmeister, Jacki J ^b   Jungbauer, Lisa ^c   Welzel, Alfred T ^d   Yu, Chunjiang ^c   Sherman, Mathew A ^a   Lesné, Sylvain ^a   LaDu, Mary Jo ^c   Walsh, Dominic M ^d   Ashe, Karen H ^a,b   Cleary, James P ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

A ; Alzheimer's disease; Amyloid peptide; Cognition; Oligomers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; DIMER; MONOMER; OLIGOMER; TRIMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHO CELL; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; FOREBRAIN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; RAT; SYNTHESIS; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; CHO CELLS; CHROMATOGRAPHY, GEL; COGNITION DISORDERS; CRICETINAE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENTRICULAR; MICE; MICE, TRANSGENIC; MICROSCOPY, ATOMIC FORCE; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RATS; SILVER STAINING; TRANSFECTION;

EID: 80051665699     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.11.007     Document Type: Article

References (27)

1. Bitan G., Fradinger E.A., Spring S.M., Teplow D.B. Neurotoxic protein oligomers: what you see is not always what you get. Amyloid 2005, 12(2):88-95.
2. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8(1):79-84.
3. Chen Y.R., Glabe C.G. Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides abeta40 and abeta42: stable trimer or tetramer formation by aveta42. J. Biol. Chem. 2006, 281(34):24414-24422.
4. Dahlgren K.N., Manelli A.M., Blaine Stine W., Baker L.K., Krafft G.A., Ladu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002, 277(35):32046-32053.
5. Hepler R.W., Grimm K.M., Nahas D.D., Breese R., Dodson E.C., Acton P., Keller P.M., Yeager M., Wang H., Shughrue P., Kinney G., Joyce J.G. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 2006, 45(51):15157-15167.
6. Hsiao K. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
7. Koo E.H., Squazzo S.L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 1994, 269(26):17386-17389.
8. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Roxovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6448-6453.
9. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440(7082):352-357.
10. Manelli A.M., Bulfinch L.C., Sullivan P.M., LaDu M.J. Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol. Aging 2007, 28(8):1139-1147.
11. Mattson M.P., Cheng B., Culwell A.R., Esch F.S., Lieberburg I., Rydel R.E. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the [beta]-amyloid precursor protein. Neuron 1993, 10(2):243-254.
12. Morishima-Kawashima M., Ihara I. The presence of amyloid b-portein in the detergent-soluble membrane compartment of human neuroblastoma cells. Biochemistry. 1998, 37(44):15247-15253.
13. O'Hare E., Levine A.S., Semotuk M.T., Tierney K.J., Shephard R.A., Grace M.K., Cleary J. Utilization of a novel model of food reinforced behavior involving neuropeptide Y, insulin, 2-deoxy-d-glucose and naloxone. Behav. Pharmacol. 1996, 7(8):742-753.
14. Podlisny M.B., Ostaszewski B.L., Squazzo S.L., Koo E.H., Rydell R.E., Teplow D.B., Selkoe D.J. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 1995, 270(16):9564-9570.
15. Richardson R.L., Kim E.M., Shephard R.A., Gardiner T., Cleary J., O'Hare E. Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res. 2002, 954(1):1-10.
16. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh, D.M., Sabatini, B.L., Selkoe, D.J., 2008. Amyloid-[beta] protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. advanced online publication.
17. Stenh C., Englund H., Lord A., Johansson A., Almeida C.G., Gellerfors P., Greengard P., Gouras G.K., Lannfelt L., Nilsson L.N. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann. Neurol. 2005, 58(1):147-150.
18. Stine W.B., Dahlgren K.N., Krafft G.A., Ladu M.J. In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J. Biochem. 2003, 278(13):11612-11622.
19. Townsend M., Cleary J.P., Mehta T., Hofmeister J., Lesné S., O'Hare E., Walsh D.M., Selkoe D.J. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann. Neurol. 2006, 60(6):668-676.
20. Townsend M., Shankar G.M., Mehta T., Walsh D.M., Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 2006, 572(Pt 2):477-492.
21. Trommer B.L., Shah C., Yun S.H., Gamkrelidze G., Pasternak E.S., Stine W.B., Manelli A., Sullivan P., Pasternak J.F., LaDu M.J. ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. Neurobiol. Dis. 2005, 18(1):75-82.
22. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39(35):10831-10839.
23. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416(6880):535-539.
24. Walsh D.M., Klyubin I., Shankar G.M., Townsend M., Fadeeva J.V., Betts V., Podlisny M.B., Cleary J.P., Ashe K.H., Rowan M.J., Selkoe D.J. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans. 2005, 33(Pt 5):1087-1090.
25. Walsh D.M., Selkoe D.J. A beta oligomers-a decade of discovery. J. Neurochem. 2007, 101(5):1172-1184.
26. Wang Q., Walsh D.M., Rowan M.J., Selkoe D.J., Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 2004, 24(13):3370-3378.
27. Yun S.H., Gamkrelidze G., Stine W.B., Sullivan P.M., Pasternak J.F., Ladu M.J., Trommer B.L. Amyloid-beta1-42 reduces neuronal excitability in mouse dentate gyrus. Neurosci. Lett. 2006, 403(1-2):162-165.